Literature DB >> 28489982

Triple-Negative Breast Cancer: Current Practice and Future Directions.

Ricardo L B Costa1, William J Gradishar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28489982     DOI： 10.1200/JOP.2017.023333

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  26 in total

1.  A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

Authors:  Cody J Peer; Keith T Schmidt; Jessica D Kindrick; Joel R Eisner; Victoria V Brown; Edwina Baskin-Bey; Ravi Madan; William D Figg
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-31       Impact factor: 3.333

Review 2.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

3.  Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.

Authors:  Li-Ping Ge; Xi Jin; Yun-Song Yang; Xi-Yu Liu; Zhi-Ming Shao; Gen-Hong Di; Yi-Zhou Jiang
Journal:  Oncogene       Date:  2021-03-02       Impact factor: 9.867

4.  The IncRNA BORG: A novel inducer of TNBC metastasis, chemoresistance, and disease recurrence.

Authors:  Alex J Gooding; Kimberly A Parker; Saba Valadkhan; William P Schiemann
Journal:  J Cancer Metastasis Treat       Date:  2019-05-10

5.  The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.

Authors:  Aileen I Fernandez; Xue Geng; Krysta Chaldekas; Brent Harris; Anju Duttargi; V Layne Berry; Deborah L Berry; Akanksha Mahajan; Luciane R Cavalli; Balázs Győrffy; Ming Tan; Rebecca B Riggins
Journal:  Breast Cancer Res Treat       Date:  2019-11-19       Impact factor: 4.872

Review 6.  Cancer microenvironment and genomics: evolution in process.

Authors:  Stanley P Leong; Isaac P Witz; Orit Sagi-Assif; Sivan Izraely; Jonathan Sleeman; Brian Piening; Bernard A Fox; Carlo B Bifulco; Rachel Martini; Lisa Newman; Melissa Davis; Lauren M Sanders; David Haussler; Olena M Vaske; Marlys Witte
Journal:  Clin Exp Metastasis       Date:  2021-05-10       Impact factor: 5.150

Review 7.  Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity.

Authors:  Rachel Martini; Lisa Newman; Melissa Davis
Journal:  Clin Exp Metastasis       Date:  2021-05-05       Impact factor: 4.510

8.  A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.

Authors:  Manpreet Sambi; Vanessa Samuel; Bessi Qorri; Sabah Haq; Sergey V Burov; Elena Markvicheva; William Harless; Myron R Szewczuk
Journal:  Drug Des Devel Ther       Date:  2020-05-25       Impact factor: 4.162

9.  In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.

Authors:  Brett Fleisher; Jovin Lezeau; Carolin Werkman; Brehanna Jacobs; Sihem Ait-Oudhia
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-18

10.  A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.

Authors:  Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-27       Impact factor: 3.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.